Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine.
Recently, we developed and optimized a new method for the evaluation of the protective properties of serotype 2 inactivated poliovirus vaccines (IPV). The method is based on the immunization and subsequent challenge of transgenic (Tg) mice susceptible to poliovirus. We describe a similar method for the assessment of the protectiveness of serotype 1 IPV and demonstrate that experimental IPV produced from attenuated Sabin strain (sIPV) of serotype 1 poliovirus induced serum neutralizing antibodies, immunoglobulin (Ig) G, IgM, and salivary IgA at titers comparable to those induced by conventional IPV (cIPV) produced from the wild-type Mahoney strain. In contrast to our previous results with serotype 2 sIPV, serotype 1 sIPV provided even better protection of Tg mice than cIPV against challenge with wild-type Mahoney strain.
Dragunsky
Eugenia M
EM
Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA. eugenia.dragunsky@fda.hhs.gov
Ivanov
Alexander P
AP
Abe
Shinobu
S
Potapova
Svetlana G
SG
Enterline
Joan C
JC
Hashizume
So
S
Chumakov
Konstantin M
KM
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D003429:Cross Reactions / Q000276:immunology; D004195:Disease Models, Animal; D005260:Female; D007136:Immunoglobulins / Q000032:analysis; D008297:Male; D051379:Mice; D008822:Mice, Transgenic / Q000276:immunology* / Q000821:virology; D011051:Poliomyelitis / Q000517:prevention & control*; D017955:Poliovirus / Q000276:immunology*; D011054:Poliovirus Vaccine, Inactivated / Q000276:immunology*; D014611:Vaccination / Q000379:methods
D000914:Antibodies, Viral; D007136:Immunoglobulins; D011054:Poliovirus Vaccine, Inactivated